6,074 Danaher Corporation $DHR Shares Sold by Loring Wolcott & Coolidge Fiduciary Advisors LLP MA

Key Points

• Loring Wolcott & Coolidge Fiduciary Advisors reduced its Danaher stake by 6,074 shares, or 0.4%, but still held 1.67 million shares worth approximately $370.3 million. Institutional investors collectively own 79.05% of DHR.
• Danaher reported quarterly adjusted EPS of $2.11, beating estimates of $1.92, while revenue rose 8.3% year over year to $6.55 billion. Management also raised its full-year 2026 adjusted EPS outlook.
• Analysts remain broadly bullish, with a consensus “Moderate Buy” rating and a $242.91 price target, although tariff pressure, execution concerns and a cautious 2027 outlook present risks. Danaher also declared a quarterly dividend of $0.40 per share.

Loring Wolcott & Coolidge Fiduciary Advisors LLP MA trimmed its holdings in shares of Danaher Corporation (NYSE:DHR - Free Report) by 0.4% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,671,318 shares of the conglomerate's stock after selling 6,074 shares during the quarter. Danaher makes up approximately 3.5% of Loring Wolcott & Coolidge Fiduciary Advisors LLP MA's investment portfolio, making the stock its 7th largest position. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA owned approximately 0.24% of Danaher worth $370,281,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in DHR. BlackRock Inc. acquired a new position in shares of Danaher during the 2nd quarter worth about $10,492,520,000. Jupiter Topco LLC acquired a new stake in Danaher in the 2nd quarter worth about $1,456,317,000. Generation Investment Management LLP purchased a new stake in Danaher during the 2nd quarter worth approximately $1,287,949,000. Bank of America Corp DE purchased a new stake in Danaher during the 2nd quarter worth approximately $993,846,000. Finally, Legal & General Group Plc purchased a new stake in Danaher during the 2nd quarter worth approximately $801,056,000. Hedge funds and other institutional investors own 79.05% of the company's stock.

Danaher Stock Performance

DHR opened at $230.36 on Monday. Danaher Corporation has a twelve month low of $160.93 and a twelve month high of $242.80. The firm has a market capitalization of $162.07 billion, a PE ratio of 37.70, a PEG ratio of 2.89 and a beta of 0.76. The company has a current ratio of 1.63, a quick ratio of 1.29 and a debt-to-equity ratio of 0.45. The firm's 50-day moving average price is $216.32 and its 200 day moving average price is $197.39.

Danaher (NYSE:DHR - Get Free Report) last released its quarterly earnings data on Wednesday, October 21st. The conglomerate reported $2.11 EPS for the quarter, beating analysts' consensus estimates of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The company had revenue of $6.55 billion during the quarter, compared to the consensus estimate of $6.56 billion. During the same quarter in the prior year, the firm earned $1.89 EPS. Danaher's quarterly revenue was up 8.3% on a year-over-year basis. As a group, sell-side analysts expect that Danaher Corporation will post 8.59 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Stockholders of record on Wednesday, September 30th will be given a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a dividend yield of 0.7%. Danaher's dividend payout ratio is 26.19%.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Danaher reported third-quarter adjusted earnings of $2.11 per share, above the $1.92 analyst consensus, while revenue reached approximately $6.55 billion. Revenue increased 8.3% year over year, and management raised its full-year 2026 adjusted EPS outlook. Danaher 3Q Net Up Sharply as Company Boosts 2026 Adjusted EPS View
• Positive Sentiment: Analysts raised their valuation targets following the results. TD Cowen and JPMorgan lifted targets to $270, Goldman Sachs raised its target to $275, Stifel increased its target to $260, and Robert W. Baird raised its target to $254. The firms maintained bullish ratings, including Buy, Overweight and Outperform. Danaher Analysts Raise Their Forecasts Following Better-Than-Expected Q3 Earnings
• Positive Sentiment: Management highlighted margin strength, improved execution and an increased focus on innovation and artificial intelligence, factors analysts viewed as supporting a better longer-term outlook. Danaher Earnings Call Highlights Margin Strength, AI Push
• Neutral Sentiment: Despite the earnings beat and higher targets, shares declined in the immediate post-results reaction, suggesting investors may have already priced in much of the improvement. A recent valuation comparison also frames DHR as a stock for investors weighing quality and growth against its relatively elevated valuation. Danaher Q3 Recap: Decent Results, Still A Hold
• Negative Sentiment: Danaher’s new CEO emphasized the need for better execution and innovation. TD Cowen cited tariff pressure and a cautious 2027 outlook, creating uncertainty beyond the raised 2026 guidance and helping explain why the stock did not fully respond to the strong quarterly report. Danaher Posts First Earnings Under New CEO

Analyst Upgrades and Downgrades

DHR has been the subject of a number of research analyst reports. Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Wells Fargo & Company lowered their price target on Danaher from $212.00 to $195.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 22nd. Royal Bank Of Canada boosted their price target on Danaher from $215.00 to $250.00 and gave the stock an "outperform" rating in a research report on Monday, October 5th. Barclays increased their price objective on Danaher from $255.00 to $260.00 and gave the company an "overweight" rating in a research note on Thursday. Finally, The Goldman Sachs Group reissued a "buy" rating and issued a $275.00 price objective on shares of Danaher in a research note on Thursday. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $242.91.

Danaher Company Profile

Danaher Corporation NYSE: DHR is a global science and technology company that develops products, services and solutions for the life sciences, biotechnology and diagnostics markets. Its offerings help researchers, pharmaceutical and biotechnology companies, healthcare providers and other organizations conduct scientific research, develop and manufacture medicines, and diagnose disease.

The company operates through businesses that provide bioprocessing equipment and technologies, laboratory instruments, consumables, analytical tools and clinical diagnostic systems.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.